What is Mirvie?
Founded in 2018 and headquartered in South San Francisco, Mirvie is transforming prenatal care through its proprietary RNA-based blood test. The company addresses a significant clinical gap, as one in five pregnancies is impacted by complications that can lead to lifelong health consequences. By identifying these risks months before they manifest clinically, Mirvie provides expecting parents and healthcare providers with a vital window for intervention. The company's leadership team, comprised of seasoned scientists and entrepreneurs, has a proven track record in bringing category-first diagnostic tests to market, effectively bridging the gap between complex genomic data and actionable clinical outcomes.
How much funding has Mirvie raised?
Mirvie has raised a total of $89.5M across 3 funding rounds:
Angel/Seed
$5.8M
Series B
$60M
Stock/Share Issuance
$23.7M
Angel/Seed (2018): $5.8M with participation from Khosla Ventures
Series B (2022): $60M led by GV, General Catalyst, Mayfield, Foresite Capital, Decheng Capital, Comerica, Khosla Ventures, and BlackRock
Stock/Share Issuance (2025): $23.7M, investors not publicly disclosed
Key Investors in Mirvie
Khosla Ventures
A venture capital firm founded by Vinod Khosla that provides strategic advice and capital to entrepreneurs developing breakthrough technologies across health, AI, and enterprise sectors.
GV
A global venture capital firm that invests across multiple stages and sectors, with a strong focus on life sciences, frontier technology, and enterprise solutions.
General Catalyst
A venture capital firm that partners with founders to build enduring enterprises, applying deep sector expertise to support companies at critical inflection points in healthcare and technology.
What's next for Mirvie?
With this major enterprise-level funding, Mirvie is well-positioned to accelerate its clinical development and expand the reach of its diagnostic platform. The strategic focus will likely center on scaling commercial operations, deepening its research into pregnancy biology, and navigating the regulatory pathways required for broader clinical adoption. As the company moves beyond its early-stage roots, the focus shifts toward establishing its RNA platform as a standard of care in prenatal diagnostics, ultimately aiming to reduce the incidence of premature births and other pregnancy-related crises through proactive, data-driven health management.
See full Mirvie company page
